RAMB 07/08/2014

ate

onset

hypogonadism

ADAM:

diagnosis

ssoc

ras

2014; 60(4):286-294

293

An increase in PSA levels higher than 1.4 ng/mL in

any 12 month period during treatment;

The speed of any increase in PSA is higher than

0.4 ng/mL/year, using the PSA level after 6 months

of testosterone administration as a baseline (only va-

lid if the PSA levels are known for a period of more

than two years);

Detection of prostatic abnormality during rectal

examination

(

If the patient’s risk of prostate cancer is sufficiently high

as stated above (suspected findings during rectal exami-

nation, increase PSA and other risk factors such as age,

family history, race, etc.) an ultrasound-guided prostate

biopsy is recommended

(

)

46,47

(

Recommendation

After starting ART, patients should be monitored for pros-

tate disease, with rectal examination and PSA measure-

ments 3, 6 and 12 months after treatment, and then an-

nually, if there are no abnormalities. The patient should

undergo prostatic investigation if: PSA is higher than 4

ng/mL or 3 ng/mL in high-risk patients, an increase in

PSA higher than 1.4 ng/mL in any 12 month period du-

ring treatment, the speed of increase in PSA is higher than

0.4 ng/mL/year, using the PSA level after 6 months of tes-

tosterone administration as baseline, and detection of

prostatic abnormality during rectal examination.

eferences

Martits AM, Costa EMF. Late onset male hypogonadism or andropause.

Rev Assoc Med Bras 2004;50:358-9.

Kalache A. Gender-especific health care in the 21

century: a focus on

developing countries. aging Male 2002;5:129-38.

Lapauw B, Goemaere S, Zmierczak H, Van Pottelbergh I, Mahmoud A, Taes

Y, et al. The decline of serum testosterone levels in community-dwelling

men over 70 years of age: descriptive data and predictors of longitudinal

changes. Eur J Endocrinol 2008;159:459-68.

Sato Y, Kato S, Ohnishi S, Nakajima H, Nanbu A, Nitta T, et al. Analysis of

clinical manifestation and endocrinological aspects of patients having

PADAM-like symptoms. Nippon Hinyokika Gakkai Zasshi 2004;95:8-16.

Feldman HA, Longscope C, Derby CA, Johannes CH, Araujo AB, Coviello

Ad, et al. Age trends in the level of serum testosterone and other hormones

in middle-aged men: longitudinal results from the Massachusets Male aging

Study. J Clin Endocrinol Metab 2002;87:589-98.

Schatzl G, Madersbacher S, Temmi C, Krenn-Scnikel, Nader A, Sregi G, et

al. Serum androgen levels in men: impact of health status and age. Urology

2003;61: 629-33.

Morales A, Lunenefeld B. International Society for the Study of the aging

Male. Investigation, treatment and monitoring of late-onset hypogonadism

in males. Official recommendation of ISSAM. International Society for the

study of the aging Male. aging Male 2002:74-86.

8. Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, et al

Androtest: a structured interview for the screening of hypogonadism in

patient with sexual dysfunction. J Sex Med 2006;3:706-15.

Martínez- Jabaloyas JM, Queipo-Zaragozá A, Pastor-Hernández F, Gil-

SalomM, Chuan-Nuez P. testosterone levels in men with erectile dysfunction.

BJU Int 2006;97:1278-83.

10.

Hintikka J, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi

K, Lehto SM, et al. Hypogonadism, decreased sexual desire and long term

depression in middle-aged men.J Sex Med 2009;6:2049-57.

11. Vermeulen A, Goermarere S, Kaufman M. Sex hormones, body composition

and aging. agingMale 1999;2;8-15.

12. Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, et

al. A comparison of NCEP-ATP III and IDF metabolic syndrome definitions

with relation to metabolic syndrome-associated sexual dysfunction. J Sex

Med 2007;4:789-96.

13. Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, et al.

NCEP-ATP III-defined metabolic syndrome, type 2 diabetes mellitus, and

prevalence of hypogonadism in male patients with sexual dysfunction. J

Sex Med; 4:1038-45.

14.

Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and

increased bone resorption in elderly men with partial androgen deficiency:

the MINOS study. J Clin Endocrinol Metab 2003;88:5240-7

15. Clapauch R, Braga DJ, Marinheiro LP, Buksman S, Schrank Y. Risk of late

onset hypogonadism ( andropause) in Brazilian men over 50 years of age

with osteoporosis: usefulness of screening questionnaires. Arq Bras of

Endocrinol Metabol 2008;52:1439-47

16.

Mahmoud AM, Goemaere S, El-Garem Y, Van Pottelberg I, Comhaire FH,

Kaufman JM. Testicular volume in relation to hormonal indices of gonadal

function in community-dwelling elderly men. J. Clin Endocrinol Metab

2003;88:179-84.

17.

Kshirsagar A, Seftel A, Ross L, Mohamed M, Niederberger C. Predicting

hypogonadism in men based upon age, presence of erectile dysfunction,

and depression. Int J Impot Res 2006;06:47 PM-51.

18. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement

of total serum testosterone in adult men: comparison of current laboratory

methods versus liquid chromatography-tandem mass spectometry. J Clin

Metab 2004; 89:534-43.

19. Morley JE, Perry HM 3

, Kevorkian RT, Patrick P. Comparison of screening

questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53:424-9.

20.

Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, Mc Cready D, et al.

Validation of a screening questionnaire for androgen deficiency in aging

males. Metabolism 2000;49:1239-42.

21.

Martínez-Jabayolas JM, Queipo-Zaragozá, Rodrigues-Navarro R, Queipo-

Zaragoza JA,Gil-Salom M, Chuan-Nuez P. Relationship between the Saint

Louis University ADAM questionnaire and sexual hormonal levels in a male

outpatient population over 50 years of age. Eur Urol 2007;52:1760-7.

22. Chu LW, Tam S, Kung AW, Lam TP, Lee A, Wong RL, et al. A short version

of the ADAM Questionnaire for androgen deficiency in Chinese men. J

Gerontol A Biol Sci Med Sci 2008;63:426-31.

23. Tancredi A, Reginster JY, Schleich F, Pire G, Maassen P, Luyckx F, et al.

Interest of the androgen deficiency in aging males (ADAM) questionnaire

for the indentification of hypogonadism in elderly community- dwelling

male volunteers. Eur J Endocrinol 2004;151:355-6.

24.

Blümel JE, Chedraui P, Gili SA, Navarro A, Valenzuela K, Vallejo S. Is the

Androgen Deficiency of aging Men (ADAM) questionnaire useful for the

screening of partial androgenic deficiency of aging men? Maturitas

2009;63:365-8.

25.

Smith KW, Feldman HA, Mc Kinlay JB. Construction and field validation

of a self administered screener for testosterone deficiency ( hypogonadism)

in ageing men. Clin Endocrinol (Oxf) 2000;53:703-11.

26. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the aging

Males’ Symptoms (AMS) scale predict those of screening scales for androgen

deficiency? aging Male 2004;7:211-8.

27. Kratzik CW, Reiter WJ, Riedl AM, Lunglmayr G, Brandstëtter N, Rücklinger

E, et al. Hormone profiles, body mass index and aging male symptoms: results

of the Androx Vienna Municipality study. aging Male 2004;7:188-96.

28. Kratzik C, Heinemann LA, Saad F, Thai DM, Rücklinger E. Composite screener

for androgen deficiency related to the aging Males’ Symptoms scale. aging

Male 2005;8:157-61.

29.

Matsumoto A, Bremner W. Serum testosterone assays- accuracy matters. J

Clin Endocrinol Metab. 2004;89:520-4.

30. Wang C, Nieschlag E, Swerdloff, RS, Behre H, HellstromWJ, Gooren LJ, et al.

ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment

and monitoring of late-onset hypogonadism in males. aging Male 2009;12:05

AM-12.

SCIELO.indb 293

8/1/14 2:28 PM